Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Decreases By 7.4%

Biodesix, Inc. (NASDAQ:BDSX) was the target of a large drop in short interest in January. As of January 15th, there was short interest totalling 836,600 shares, a drop of 7.4% from the December 31st total of 903,100 shares. Based on an average daily volume of 420,900 shares, the days-to-cover ratio is currently 2.0 days.

Biodesix Trading Down 1.9 %

Biodesix stock traded down $0.02 during trading hours on Monday, reaching $1.01. 193,655 shares of the company’s stock were exchanged, compared to its average volume of 476,998. Biodesix has a twelve month low of $0.86 and a twelve month high of $2.21. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The firm’s 50 day simple moving average is $1.31 and its 200 day simple moving average is $1.53. The firm has a market capitalization of $146.92 million, a PE ratio of -2.59 and a beta of 1.06.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Friday, November 1st. The company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $18.15 million for the quarter, compared to analyst estimates of $18.45 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. During the same quarter last year, the company earned ($0.12) earnings per share. Research analysts predict that Biodesix will post -0.35 earnings per share for the current year.

Insider Buying and Selling

In other Biodesix news, Chairman John Patience acquired 75,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were purchased at an average price of $1.38 per share, for a total transaction of $103,500.00. Following the completion of the purchase, the chairman now directly owns 2,153,298 shares of the company’s stock, valued at approximately $2,971,551.24. This represents a 3.61 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Matthew Strobeck acquired 40,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were purchased at an average price of $1.40 per share, for a total transaction of $56,000.00. Following the transaction, the director now directly owns 2,606,879 shares in the company, valued at approximately $3,649,630.60. This trade represents a 1.56 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 315,000 shares of company stock worth $393,500 in the last quarter. 69.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Biodesix

A number of institutional investors have recently added to or reduced their stakes in the business. Barclays PLC raised its stake in Biodesix by 1,140.5% during the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after buying an additional 21,179 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in Biodesix during the third quarter valued at approximately $262,000. Stephens Inc. AR bought a new position in shares of Biodesix in the fourth quarter worth about $303,000. Perkins Capital Management Inc. lifted its holdings in shares of Biodesix by 74.7% in the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after buying an additional 310,000 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Biodesix by 50.7% during the third quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock valued at $1,433,000 after purchasing an additional 270,724 shares in the last quarter. 20.96% of the stock is currently owned by institutional investors.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.